Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 14th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 14th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 16th 2017

Advanced APMs and the Emerging Role of Immuno-Oncology Agents: Balancing Innovation and Value

Michael V. Seiden, MD, PhD Marcus Neubauer, MD Diana Verrilli

The shift to value-based care, concurrent with innovations in immune-based care, will create challenges in oncology. What should be the physician and manufacturer responsibility during these changing times?

February 16th 2017

Helping Cancer Patients and Caregivers Navigate Immunotherapy Treatment

Claire Saxton, MBA Joanne Buzaglo, PhD Sue Rochman, MA Alexandra Zaleta, PhD

Patients, caregivers, and providers need education on immunotherapy treatment, support in patient-provider communications as well as support in mitigating the financial impact of immunotherapy treatment.

February 16th 2017

Postmenopausal Weight Loss Cuts Risk of Endometrial Cancer by Half

Surabhi Dangi-Garimella, PhD

Observational findings from the Women’s Health Initiative study found that an intentional weight loss regimen by postmenopausal obese women can slash their risk of endometrial cancer by 29% to 56%.

February 16th 2017

Dr Marianne Fazen Discusses New Ways to Educate Employers on Value in Cancer Care

Through the use of workshops and other productions, the Texas Business Group on Health educates employers on how they can maximize value through oncology care innovations like precision medicine, according to Marianne Fazen, PhD, president and CEO of the Texas Business Group on Health.

February 15th 2017

UCSF Researchers Identify Determinants of Coverage for Hereditary Cancer Panels

Surabhi Dangi-Garimella, PhD

A new study published in the Journal of the National Comprehensive Cancer Network dives deeper into understanding the major roadblocks to coverage of hereditary cancer panels.

February 15th 2017

Breast Cancer Survivors Report More Cognitive Impairment After Chemotherapy

Christina Mattina

A study of breast cancer survivors’ cognitive performance before and after chemotherapy sheds light on the problem of cancer-related cognitive impairment.

February 15th 2017

From Bench to Community Oncology Clinic: The Promise of Immunotherapy

Sumeet Chandra, MD

Community oncologists will be at the forefront of using immunotherapies and will need to be strong advocates for greater information and affordability of therapies.

February 15th 2017

Managing Patient Expectations With Immuno-Oncology

Surabhi Dangi-Garimella, PhD

Immunotherapy treatments are not without side effects. What do patients and their families need to know so they are more aware?

February 15th 2017

Dr Karen van Caulil Says Employers Will See Value of OCM

Employers are generally not very familiar with the Oncology Care Model (OCM) yet, but support will grow as they see that the key goals of the OCM overlap with their own concerns, predicted Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition.

February 14th 2017

CAR-T Cells: The Next Era in Immuno-Oncology

Bruce A. Feinberg, DO Jennifer Fillman, MBA Justin Simoncini, MBA, MPH Chadi Nabhan, MD, MBA, FACP

An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.

February 14th 2017

Sustained Response to Immune Checkpoint Inhibitors Could Influence Standard of Care

Surabhi Dangi-Garimella, PhD

A new study to be presented at the 2017 Genitourinary Cancers Symposium has found that some patients with advanced renal cell carcinoma had a durable response after treatment discontinuation.

February 14th 2017

Patient Navigation in Immuno-Oncology

Shawn M. Regis, PhD

Patient navigation is immensely helpful in relieving some of the burden placed on cancer patients, and there are some particularly unique aspects of navigation as it pertains to immuno-oncology.

February 13th 2017

AJMCtv® Interviews, February 2017

Nicole Beagin Laura Joszt, MA

AJMCtvÂ® interviews let you catch up with experts in healthcare. Topics include challenges with immuno-oncology, including the patient voice in treatment decisions, and why payers should cover genomic testing.

February 13th 2017

Navigator Program Lowered Costs, Utilization for Elderly Cancer Patients

Christina Mattina

A program linking elderly cancer patients to lay navigators was shown to substantially reduce costs and decrease hospitalizations, making it an appealing tool for providing value-based oncology care.

February 13th 2017

Predicting Response to SCT in Patients With MDS

Surabhi Dangi-Garimella, PhD

A new study has identified key mutations that can direct the conditioning regimen prior to an allogenic hematopoietic stem cell transplant (SCT) in patients with myelodysplastic syndrome (MDS), leading to a better response.

February 13th 2017

Debra Madden Discusses Importance of Educating Patients on Immuno-Oncology Risks

Immuno-oncology is often portrayed as having less severe side effects than chemotherapy, but patients need to be aware that it does carry some risks, said Debra L. Madden, cancer research advocate and patient representative. Patients should not hesitate to report any adverse effects to their doctor.

February 12th 2017

MD Anderson Now an Oncology "Superhub" for Project ECHO

Surabhi Dangi-Garimella, PhD

MD Anderson Cancer Center, which first established its oncology-focused ECHO program in 2014 has now adopted a much bigger role, of a “superhub.”

February 11th 2017

Podcast: This Week in Managed Care - Drop in ACA Enrollment, and Other News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 10th 2017

This Week in Managed Care: February 10, 2017

This week, the top managed care stories included final enrollment numbers for the Affordable Care Act for 2017, a report that revealed low rates of lung cancer screening, and a study found that a population-based weight management strategies can prevent diabetes.

February 10th 2017

The Complex Relation Between Clinical Outcomes, Drug Approval, and Drug Price

Surabhi Dangi-Garimella, PhD

Does an FDA approval guarantee clinical benefit of a drug? How does it influence drug price?

February 9th 2017

Hopkins' Researchers Discover Carcinogenic Metals in E-Cigarette Liquid

Surabhi Dangi-Garimella, PhD

Analysis of the liquid used to make the aerosol in e-cigarettes has led to the discovery of high levels of 5 potentially toxic heavy metals.

February 8th 2017

Michigan Study Finds Obesity Lowers Hospice Use Among Seniors

Surabhi Dangi-Garimella, PhD

A long-term health study has found that seniors with a higher body mass index were less likely to make use of hospice care. Additionally, obese seniors spent significantly fewer days in hospice care than their nonobese counterparts.

February 8th 2017

Breast Cancer Patients Not Getting Desired Genetic Testing, Counseling

Christina Mattina

A recent JAMA study found that women with breast cancer would generally like to receive genetic testing and counseling, but less than one-third actually receive it.

February 7th 2017

PMC Report Proposes Strategies for Clinical Integration of Personalized Medicine

Surabhi Dangi-Garimella, PhD

The Health Care Working Group of the Personalized Medicine Coalition (PMC) has published a new report that provides a framework for the successful integration of personalized medicine in the clinic.

February 7th 2017

Low-Income Women Less Likely to Keep Jobs After Breast Cancer Treatment

Christina Mattina

Women with breast cancer are twice as likely to return to work after treatment if their employer makes accommodations for them, but workplace accommodation and job retention are significantly lower for low-income and minority women.

February 6th 2017

ACS Study Voices Concerns Over Low US Lung Cancer Screening Rates

Surabhi Dangi-Garimella, PhD

Lung cancer screening rates in the United States remained low and unchanged in 2015 despite recommendations that high-risk current and former smokers be screened.

February 6th 2017

David Fabrizio Explores Complexities of Surrogate Endpoints in Cancer Clinical Trials

The FDA has been willing to explore the utilization of surrogate endpoints like tumor response in clinical trials, but it is unclear whether these endpoints correlate with overall survival, said David Fabrizio of Foundation Medicine, Inc. However, he emphasized that overall survival does not necessarily benefit the patient if the additional days gained are not quality days.

February 6th 2017

Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data

Cancer Outcomes Tracking and Analytics (COTA) focuses on stratifying cancer patients by their many subtypes to understand the different treatments, outcomes, and costs for each, according to Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

February 2nd 2017

Report Commissioned by COA Explores "Murky" World of Pharmacy DIR Fees

Christina Mattina

A white paper commissioned by the Community Oncology Alliance (COA) delved into the practice of “direct and indirect remuneration” fees administered by pharmacy benefit managers and how they could drive up drug prices for Medicare Part D beneficiaries and taxpayers.

February 1st 2017

Pembrolizumab Now Approved for First-Line Treatment of Lung Cancer in Europe and the US

AJMC Staff

Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.

...

83 84 85 86 87 88 89 90 91

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions